NVAX vs. OCGN

In the year-to-date period, NVAX achieves a -21.77% return, which is significantly lower than OCGN's -11.89% return. Over the past 10 years, NVAX has outperformed OCGN with an annualized return of -28.33%, while OCGN has yielded a comparatively lower -47.86% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and Ocugen, Inc. (OCGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NVAX Sharpe Ratio is -0.55, which is higher than the OCGN Sharpe Ratio of -0.83. The chart below compares the historical Sharpe Ratios of NVAX and OCGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NVAX nor OCGN has paid dividends to shareholders.

The maximum NVAX drawdown since its inception was -98.82%, roughly equal to the maximum OCGN drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for NVAX and OCGN. For additional features, visit the drawdowns tool.

Novavax, Inc. (NVAX) has a higher volatility of 29.26% compared to Ocugen, Inc. (OCGN) at 16.91%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than OCGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Novavax, Inc. and Ocugen, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.